Charles River Laboratories International, Inc.
CRL
$163.71
-$0.40-0.24%
NYSE
| 06/28/2025 | 03/29/2025 | 12/28/2024 | 09/28/2024 | 06/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.59% | -2.71% | -1.08% | -1.64% | -3.19% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.59% | -2.71% | -1.08% | -1.64% | -3.19% |
| Cost of Revenue | -1.49% | -2.23% | 4.48% | -1.31% | 0.00% |
| Gross Profit | 4.30% | -3.59% | -11.43% | -2.21% | -8.42% |
| SG&A Expenses | 12.04% | -0.51% | 0.06% | 7.49% | -16.21% |
| Depreciation & Amortization | -10.73% | 16.84% | 21.17% | -5.33% | -16.06% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.83% | -1.32% | 4.15% | 0.31% | -4.22% |
| Operating Income | -0.62% | -10.70% | -37.95% | -11.62% | 2.22% |
| Income Before Tax | -40.31% | -63.66% | -203.87% | -19.16% | -7.00% |
| Income Tax Expenses | -26.26% | -58.82% | -115.41% | -15.72% | -13.10% |
| Earnings from Continuing Operations | -44.10% | -65.26% | -213.12% | -20.14% | -5.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -103.89% | 73.13% | 59.96% | -0.95% | 92.57% |
| Net Income | -44.38% | -65.09% | -214.65% | -20.29% | -3.03% |
| EBIT | -0.62% | -10.70% | -37.95% | -11.62% | 2.22% |
| EBITDA | 26.18% | -7.03% | -17.24% | -4.13% | 4.93% |
| EPS Basic | -39.01% | -61.60% | -215.69% | -21.58% | -7.85% |
| Normalized Basic EPS | 6.31% | -20.38% | -67.82% | -5.71% | 8.30% |
| EPS Diluted | -39.08% | -61.53% | -216.41% | -21.30% | -7.94% |
| Normalized Diluted EPS | 6.56% | -20.13% | -67.62% | -5.46% | 8.21% |
| Average Basic Shares Outstanding | -4.66% | -1.48% | -0.34% | 0.22% | 0.65% |
| Average Diluted Shares Outstanding | -4.88% | -1.78% | -0.94% | -0.05% | 0.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |